Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT02173379
Registration number
NCT02173379
Ethics application status
Date submitted
9/06/2014
Date registered
25/06/2014
Date last updated
30/10/2023
Titles & IDs
Public title
Absorb IV Randomized Controlled Trial
Query!
Scientific title
A Clinical Evaluation of Absorb™ BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects With de Novo Native Coronary Artery Lesions
Query!
Secondary ID [1]
0
0
10-392 C
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Coronary Artery Disease
0
0
Query!
Coronary Artery Stenosis
0
0
Query!
Coronary Disease
0
0
Query!
Coronary Stenosis
0
0
Query!
Condition category
Condition code
Cardiovascular
0
0
0
0
Query!
Coronary heart disease
Query!
Cardiovascular
0
0
0
0
Query!
Other cardiovascular diseases
Query!
Cardiovascular
0
0
0
0
Query!
Diseases of the vasculature and circulation including the lymphatic system
Query!
Other
0
0
0
0
Query!
Research that is not of generic health relevance and not applicable to specific health categories listed above
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Devices - Absorb BVS
Treatment: Devices - XIENCE
Experimental: Absorb BVS - Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
Active Comparator: XIENCE - Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) and XIENCE ProX (outside of the US only)
Treatment: Devices: Absorb BVS
Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
Once Absorb GT1™ BVS System is commercially available, it can also be used in the ABSORB IV trial. Scaffold diameters: 2.5, 3.0 and 3.5 mm of and scaffold lengths: 8, 12, 18, 23, and 28 mm.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length = 24 mm) with a reference vessel diameter of = 2.5 mm and = 3.75 mm.
Treatment: Devices: XIENCE
Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm. The 3.25 mm is only available for XIENCE Xpedition
Stent lengths: 8, 12, 15, 18, 23, and 28 mm
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length = 24 mm) with a reference vessel diameter of = 2.5 mm and = 3.75 mm.
Query!
Intervention code [1]
0
0
Treatment: Devices
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Number of Participants With Target Lesion Failure (TLF)
Query!
Assessment method [1]
0
0
Target lesion failure (TLF) composite of Cardiac Death, Myocardial Infarction attributable to Target Vessel (TV-MI), or Ischemia-Driven Target Lesion Revascularization (ID-TLR))
Query!
Timepoint [1]
0
0
30 days
Query!
Secondary outcome [1]
0
0
TLF at 1-year, Non-inferiority Against the Control
Query!
Assessment method [1]
0
0
One-sided p-value by using Farrington-Manning non-inferiority test will be used with non-inferiority margin of 4.8%, to be compared with a one-sided significance level of 0.025.
Query!
Timepoint [1]
0
0
1 year
Query!
Secondary outcome [2]
0
0
Angina at 1-year, Non-inferiority Against the Control
Query!
Assessment method [2]
0
0
Angina is defined as any angina or angina equivalent symptoms determined by the physician and/or research coordinator after interview of the patient, and as adjudicated by a clinical events committee (CEC).
This analysis will exclude angina or angina equivalent symptoms that occurred following the index procedure through hospital discharge or 7 days, whichever occurs first.
Query!
Timepoint [2]
0
0
1 year
Query!
Secondary outcome [3]
0
0
Percentage of Target Lesion With Acute Success- Device Success (Lesion Level Analysis)
Query!
Assessment method [3]
0
0
Successful delivery and deployment of the study scaffold/stent at the intended target lesion and successful withdrawal of the delivery system with attainment of final in-scaffold/stent residual stenosis of less than 30% by quantitative coronary angiography (QCA) (by visual estimation if QCA unavailable). When bailout scaffold/stent is used, the success or failure of the bailout scaffold/stent delivery and deployment is not one of the criteria for device success.
Query!
Timepoint [3]
0
0
In-hospital (= 7days)
Query!
Secondary outcome [4]
0
0
Number of Participants With Acute Success- Procedural Success (Subject Level Analysis)
Query!
Assessment method [4]
0
0
Achievement of final in-scaffold/stent residual stenosis of less than 30% by QCA (by visual estimation if QCA unavailable) with successful delivery and deployment of at least one study scaffold/stent at the intended target lesion and successful withdrawal of the delivery system for all target lesions without the occurrence of cardiac death, target vessel MI or repeat TLR during the hospital stay (maximum of 7 days).
Query!
Timepoint [4]
0
0
In-hospital (= 7days)
Query!
Secondary outcome [5]
0
0
Number of Death (Cardiac, Vascular, Non-cardiovascular)
Query!
Assessment method [5]
0
0
Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Query!
Timepoint [5]
0
0
In-hospital (= 7 days post index procedure)
Query!
Secondary outcome [6]
0
0
Number of Death (Cardiac, Vascular, Non-cardiovascular)
Query!
Assessment method [6]
0
0
Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Query!
Timepoint [6]
0
0
30 days
Query!
Secondary outcome [7]
0
0
Number of Death (Cardiac, Vascular, Non-cardiovascular)
Query!
Assessment method [7]
0
0
Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Query!
Timepoint [7]
0
0
90 days
Query!
Secondary outcome [8]
0
0
Number of Death (Cardiac, Vascular, Non-cardiovascular)
Query!
Assessment method [8]
0
0
Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Query!
Timepoint [8]
0
0
180 days
Query!
Secondary outcome [9]
0
0
Number of Death (Cardiac, Vascular, Non-cardiovascular)
Query!
Assessment method [9]
0
0
Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Query!
Timepoint [9]
0
0
270 days
Query!
Secondary outcome [10]
0
0
Number of Death (Cardiac, Vascular, Non-cardiovascular)
Query!
Assessment method [10]
0
0
Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Query!
Timepoint [10]
0
0
1 year
Query!
Secondary outcome [11]
0
0
Number of Death (Cardiac, Vascular, Non-cardiovascular)
Query!
Assessment method [11]
0
0
Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Query!
Timepoint [11]
0
0
2 years
Query!
Secondary outcome [12]
0
0
Number of Death (Cardiac, Vascular, Non-cardiovascular)
Query!
Assessment method [12]
0
0
Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Query!
Timepoint [12]
0
0
3 years
Query!
Secondary outcome [13]
0
0
Number of Death (Cardiac, Vascular, Non-cardiovascular)
Query!
Assessment method [13]
0
0
Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Query!
Timepoint [13]
0
0
4 years
Query!
Secondary outcome [14]
0
0
Number of Death (Cardiac, Vascular, Non-cardiovascular)
Query!
Assessment method [14]
0
0
Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment. Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
For the All-Cause Mortality data, the denominator excludes participants who are lost-to-follow-up or withdrawn (by subject or physician) through a given timepoint without any DMR event (all death, MI and revascularization, respectively). If these participants were included in the denominator in each arm, that would equate to assuming that these participants are alive, potentially underestimating the death rate by inflating the denominator.
Query!
Timepoint [14]
0
0
5 years
Query!
Secondary outcome [15]
0
0
Number of Participants With Myocardial Infarction (MI)
Query!
Assessment method [15]
0
0
Attributable to target vessel (TV-MI)
Not attributable to target vessel (NTV-MI)
Query!
Timepoint [15]
0
0
In-hospital (= 7 days post index procedure)
Query!
Secondary outcome [16]
0
0
Number of Participants With Myocardial Infarction (MI)
Query!
Assessment method [16]
0
0
Attributable to target vessel (TV-MI)
Not attributable to target vessel (NTV-MI)
Query!
Timepoint [16]
0
0
30 days
Query!
Secondary outcome [17]
0
0
Number of Participants With Myocardial Infarction (MI)
Query!
Assessment method [17]
0
0
Attributable to target vessel (TV-MI)
Not attributable to target vessel (NTV-MI)
Query!
Timepoint [17]
0
0
90 days
Query!
Secondary outcome [18]
0
0
Number of Participants With Myocardial Infarction (MI)
Query!
Assessment method [18]
0
0
Attributable to target vessel (TV-MI)
Not attributable to target vessel (NTV-MI)
Query!
Timepoint [18]
0
0
180 days
Query!
Secondary outcome [19]
0
0
Number of Participants With Myocardial Infarction (MI)
Query!
Assessment method [19]
0
0
Attributable to target vessel (TV-MI)
Not attributable to target vessel (NTV-MI)
Query!
Timepoint [19]
0
0
270 days
Query!
Secondary outcome [20]
0
0
Number of Participants With Myocardial Infarction (MI)
Query!
Assessment method [20]
0
0
Attributable to target vessel (TV-MI)
Not attributable to target vessel (NTV-MI)
Query!
Timepoint [20]
0
0
1 year
Query!
Secondary outcome [21]
0
0
Number of Participants With Myocardial Infarction (MI)
Query!
Assessment method [21]
0
0
Attributable to target vessel (TV-MI)
Not attributable to target vessel (NTV-MI)
Query!
Timepoint [21]
0
0
2 years
Query!
Secondary outcome [22]
0
0
Number of Participants With Myocardial Infarction (MI)
Query!
Assessment method [22]
0
0
Attributable to target vessel (TV-MI)
Not attributable to target vessel (NTV-MI)
Query!
Timepoint [22]
0
0
3 years
Query!
Secondary outcome [23]
0
0
Number of Participants With Myocardial Infarction (MI)
Query!
Assessment method [23]
0
0
Attributable to target vessel (TV-MI)
Not attributable to target vessel (NTV-MI)
Query!
Timepoint [23]
0
0
4 years
Query!
Secondary outcome [24]
0
0
Number of Participants With Myocardial Infarction (MI)
Query!
Assessment method [24]
0
0
Attributable to target vessel (TV-MI)
Not attributable to target vessel (NTV-MI)
Query!
Timepoint [24]
0
0
5 years
Query!
Secondary outcome [25]
0
0
Number of Participants With Target Vessel Myocardial Infarction (TV-MI)
Query!
Assessment method [25]
0
0
Myocardial infarction attributed to target vessel myocardial infarction (TV-MI)
Query!
Timepoint [25]
0
0
In-hospital (= 7 days post index procedure)
Query!
Secondary outcome [26]
0
0
Number of Participants With Target Vessel Myocardial Infarction (TV-MI)
Query!
Assessment method [26]
0
0
Myocardial infarction attributed to target vessel myocardial infarction (TV-MI)
Query!
Timepoint [26]
0
0
30 days
Query!
Secondary outcome [27]
0
0
Number of Participants With Target Vessel Myocardial Infarction (TV-MI)
Query!
Assessment method [27]
0
0
Myocardial infarction attributed to target vessel myocardial infarction (TV-MI)
Query!
Timepoint [27]
0
0
90 days
Query!
Secondary outcome [28]
0
0
Number of Participants With Target Vessel Myocardial Infarction (TV-MI)
Query!
Assessment method [28]
0
0
Myocardial infarction attributed to target vessel myocardial infarction (TV-MI)
Query!
Timepoint [28]
0
0
180 days
Query!
Secondary outcome [29]
0
0
Number of Participants With Target Vessel Myocardial Infarction (TV-MI)
Query!
Assessment method [29]
0
0
Myocardial infarction attributed to target vessel myocardial infarction (TV-MI)
Query!
Timepoint [29]
0
0
270 days
Query!
Secondary outcome [30]
0
0
Number of Participants With Target Vessel Myocardial Infarction (TV-MI)
Query!
Assessment method [30]
0
0
Myocardial infarction attributed to target vessel myocardial infarction (TV-MI)
Query!
Timepoint [30]
0
0
1 year
Query!
Secondary outcome [31]
0
0
Number of Participants With Target Vessel Myocardial Infarction (TV-MI)
Query!
Assessment method [31]
0
0
Myocardial infarction attributed to target vessel myocardial infarction (TV-MI)
Query!
Timepoint [31]
0
0
2 year
Query!
Secondary outcome [32]
0
0
Number of Participants With Target Vessel Myocardial Infarction (TV-MI)
Query!
Assessment method [32]
0
0
Myocardial infarction attributed to target vessel myocardial infarction (TV-MI)
Query!
Timepoint [32]
0
0
3 years
Query!
Secondary outcome [33]
0
0
Number of Participants With Target Vessel Myocardial Infarction (TV-MI)
Query!
Assessment method [33]
0
0
Myocardial infarction attributed to target vessel myocardial infarction (TV-MI)
Query!
Timepoint [33]
0
0
4 years
Query!
Secondary outcome [34]
0
0
Number of Participants With Target Vessel Myocardial Infarction (TV-MI)
Query!
Assessment method [34]
0
0
Myocardial infarction attributed to target vessel myocardial infarction (TV-MI)
Query!
Timepoint [34]
0
0
5 years
Query!
Secondary outcome [35]
0
0
Number of Participants With Target Lesion Revascularization (TLR)
Query!
Assessment method [35]
0
0
TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.
Query!
Timepoint [35]
0
0
In-hospital (= 7 days post index procedure)
Query!
Secondary outcome [36]
0
0
Number of Participants With Target Lesion Revascularization (TLR)
Query!
Assessment method [36]
0
0
TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.
Query!
Timepoint [36]
0
0
30 days
Query!
Secondary outcome [37]
0
0
Number of Participants withTarget Lesion Revascularization (TLR)
Query!
Assessment method [37]
0
0
TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.
Query!
Timepoint [37]
0
0
90 days
Query!
Secondary outcome [38]
0
0
Number of Participants With Target Lesion Revascularization (TLR)
Query!
Assessment method [38]
0
0
TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.
Query!
Timepoint [38]
0
0
180 days
Query!
Secondary outcome [39]
0
0
Number of Participants With Target Lesion Revascularization (TLR)
Query!
Assessment method [39]
0
0
TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.
Query!
Timepoint [39]
0
0
270 days
Query!
Secondary outcome [40]
0
0
Number of Participants With Target Lesion Revascularization (TLR)
Query!
Assessment method [40]
0
0
TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.
Query!
Timepoint [40]
0
0
1 year
Query!
Secondary outcome [41]
0
0
Number of Participants With Target Lesion Revascularization (TLR)
Query!
Assessment method [41]
0
0
TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.
Query!
Timepoint [41]
0
0
2 years
Query!
Secondary outcome [42]
0
0
Number of Participants With Target Lesion Revascularization (TLR)
Query!
Assessment method [42]
0
0
TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.
Query!
Timepoint [42]
0
0
3 years
Query!
Secondary outcome [43]
0
0
Number of Participants With Target Lesion Revascularization (TLR)
Query!
Assessment method [43]
0
0
TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.
Query!
Timepoint [43]
0
0
4 years
Query!
Secondary outcome [44]
0
0
Number of Participants With Target Lesion Revascularization (TLR)
Query!
Assessment method [44]
0
0
TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.
Query!
Timepoint [44]
0
0
5 years
Query!
Secondary outcome [45]
0
0
Number of Participants With Ischemia Driven TLR (ID-TLR)
Query!
Assessment method [45]
0
0
TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography
Query!
Timepoint [45]
0
0
In-hospital (= 7 days post index procedure)
Query!
Secondary outcome [46]
0
0
Number of Participants With Ischemia Driven TLR (ID-TLR)
Query!
Assessment method [46]
0
0
TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography
Query!
Timepoint [46]
0
0
30 days
Query!
Secondary outcome [47]
0
0
Number of Participants With Ischemia Driven TLR (ID-TLR)
Query!
Assessment method [47]
0
0
TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography
Query!
Timepoint [47]
0
0
90 days
Query!
Secondary outcome [48]
0
0
Number of Participants With Ischemia Driven TLR (ID-TLR)
Query!
Assessment method [48]
0
0
TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography
Query!
Timepoint [48]
0
0
180 days
Query!
Secondary outcome [49]
0
0
Number of Participants With Ischemia Driven TLR (ID-TLR)
Query!
Assessment method [49]
0
0
TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography
Query!
Timepoint [49]
0
0
270 days
Query!
Secondary outcome [50]
0
0
Number of Participants With Ischemia Driven TLR (ID-TLR)
Query!
Assessment method [50]
0
0
TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography
Query!
Timepoint [50]
0
0
1 year
Query!
Secondary outcome [51]
0
0
Number of Participants With Ischemia Driven TLR (ID-TLR)
Query!
Assessment method [51]
0
0
TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography
Query!
Timepoint [51]
0
0
2 years
Query!
Secondary outcome [52]
0
0
Number of Participants With Ischemia Driven TLR (ID-TLR)
Query!
Assessment method [52]
0
0
TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography
Query!
Timepoint [52]
0
0
3 years
Query!
Secondary outcome [53]
0
0
Number of Participants With Ischemia Driven TLR (ID-TLR)
Query!
Assessment method [53]
0
0
TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography
Query!
Timepoint [53]
0
0
4 years
Query!
Secondary outcome [54]
0
0
Number of Participants With Ischemia Driven TLR (ID-TLR)
Query!
Assessment method [54]
0
0
TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography
Query!
Timepoint [54]
0
0
5 years
Query!
Secondary outcome [55]
0
0
Number of Participants With Target Vessel Revascularization (TVR)
Query!
Assessment method [55]
0
0
TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.
TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.
TVR includes all TVR, excluding TLR
Query!
Timepoint [55]
0
0
In-hospital (= 7 days post index procedure)
Query!
Secondary outcome [56]
0
0
Number of Participants With Target Vessel Revascularization (TVR)
Query!
Assessment method [56]
0
0
TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.
TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.
TVR includes all TVR, excluding TLR
Query!
Timepoint [56]
0
0
30 days
Query!
Secondary outcome [57]
0
0
Number of Participants With Target Vessel Revascularization (TVR)
Query!
Assessment method [57]
0
0
TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.
TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.
TVR includes all TVR, excluding TLR
Query!
Timepoint [57]
0
0
90 days
Query!
Secondary outcome [58]
0
0
Number of Participants With Target Vessel Revascularization (TVR)
Query!
Assessment method [58]
0
0
TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself. classified as: Ischemic driven TVR and Non-ischemic driven TVR.
-TVR includes all TVR, excluding TLR
Query!
Timepoint [58]
0
0
180 days
Query!
Secondary outcome [59]
0
0
Number of Participants With Target Vessel Revascularization (TVR)
Query!
Assessment method [59]
0
0
TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.
TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.
TVR includes all TVR, excluding TLR
Query!
Timepoint [59]
0
0
270 days
Query!
Secondary outcome [60]
0
0
Number of Participants With Target Vessel Revascularization (TVR)
Query!
Assessment method [60]
0
0
TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.
TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.
TVR includes all TVR, excluding TLR
Query!
Timepoint [60]
0
0
1 year
Query!
Secondary outcome [61]
0
0
Number of Participants With Target Vessel Revascularization (TVR)
Query!
Assessment method [61]
0
0
TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.
TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.
TVR includes all TVR, excluding TLR
Query!
Timepoint [61]
0
0
2 years
Query!
Secondary outcome [62]
0
0
Number of Participants With Target Vessel Revascularization (TVR)
Query!
Assessment method [62]
0
0
TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.
TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.
TVR includes all TVR, excluding TLR
Query!
Timepoint [62]
0
0
3 years
Query!
Secondary outcome [63]
0
0
Number of Participants With Target Vessel Revascularization (TVR)
Query!
Assessment method [63]
0
0
TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.
TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.
TVR includes all TVR, excluding TLR
Query!
Timepoint [63]
0
0
4 years
Query!
Secondary outcome [64]
0
0
Number of Participants With Target Vessel Revascularization (TVR)
Query!
Assessment method [64]
0
0
TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.
TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.
TVR includes all TVR, excluding TLR
Query!
Timepoint [64]
0
0
5 years
Query!
Secondary outcome [65]
0
0
Number of Participants With ID-TVR Excluding TLR
Query!
Assessment method [65]
0
0
TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.
TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.
TVR includes all TVR, excluding TLR
Query!
Timepoint [65]
0
0
In-hospital (= 7 days post index procedure)
Query!
Secondary outcome [66]
0
0
Number of Participants With ID-TVR Excluding TLR
Query!
Assessment method [66]
0
0
TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.
TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.
TVR includes all TVR, excluding TLR
Query!
Timepoint [66]
0
0
30 days
Query!
Secondary outcome [67]
0
0
Number of Participants With ID-TVR Excluding TLR
Query!
Assessment method [67]
0
0
TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.
TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.
TVR includes all TVR, excluding TLR
Query!
Timepoint [67]
0
0
90 days
Query!
Secondary outcome [68]
0
0
Number of Participants With ID-TVR Excluding TLR
Query!
Assessment method [68]
0
0
TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.
TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.
TVR includes all TVR, excluding TLR
Query!
Timepoint [68]
0
0
180 days
Query!
Secondary outcome [69]
0
0
Number of Participants With ID-TVR Excluding TLR
Query!
Assessment method [69]
0
0
TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.
TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.
TVR includes all TVR, excluding TLR
Query!
Timepoint [69]
0
0
270 days
Query!
Secondary outcome [70]
0
0
Number of Participants With ID-TVR Excluding TLR
Query!
Assessment method [70]
0
0
TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.
TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.
TVR includes all TVR, excluding TLR
Query!
Timepoint [70]
0
0
1 year
Query!
Secondary outcome [71]
0
0
Number of Participants With ID-TVR Excluding TLR
Query!
Assessment method [71]
0
0
TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.
TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.
TVR includes all TVR, excluding TLR
Query!
Timepoint [71]
0
0
2 years
Query!
Secondary outcome [72]
0
0
Number of Participants With ID-TVR Excluding TLR
Query!
Assessment method [72]
0
0
TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.
TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.
TVR includes all TVR, excluding TLR
Query!
Timepoint [72]
0
0
3 years
Query!
Secondary outcome [73]
0
0
Number of Participants With ID-TVR Excluding TLR
Query!
Assessment method [73]
0
0
TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.
TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.
TVR includes all TVR, excluding TLR
Query!
Timepoint [73]
0
0
4 years
Query!
Secondary outcome [74]
0
0
Number of Participants With ID-TVR Excluding TLR
Query!
Assessment method [74]
0
0
TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.
TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.
TVR includes all TVR, excluding TLR
Query!
Timepoint [74]
0
0
5 years
Query!
Secondary outcome [75]
0
0
Number of Participants With All Coronary Revascularization
Query!
Assessment method [75]
0
0
Revascularization includes TLR, TVR excluding TLR, and non TVR.
Query!
Timepoint [75]
0
0
In-hospital (= 7 days post index procedure)
Query!
Secondary outcome [76]
0
0
Number of Participants With All Coronary Revascularization
Query!
Assessment method [76]
0
0
Revascularization includes TLR, TVR excluding TLR, and non TVR.
Query!
Timepoint [76]
0
0
30 days
Query!
Secondary outcome [77]
0
0
Number of Participants With All Coronary Revascularization
Query!
Assessment method [77]
0
0
Revascularization includes TLR, TVR excluding TLR, and non TVR.
Query!
Timepoint [77]
0
0
90 days
Query!
Secondary outcome [78]
0
0
Number of Participants With All Coronary Revascularization
Query!
Assessment method [78]
0
0
Revascularization includes TLR, TVR excluding TLR, and non TVR.
Query!
Timepoint [78]
0
0
180 days
Query!
Secondary outcome [79]
0
0
Number of Participants With All Coronary Revascularization
Query!
Assessment method [79]
0
0
Revascularization includes TLR, TVR excluding TLR, and non TVR.
Query!
Timepoint [79]
0
0
270 days
Query!
Secondary outcome [80]
0
0
Number of Participants With All Coronary Revascularization
Query!
Assessment method [80]
0
0
Revascularization includes TLR, TVR excluding TLR, and non TVR.
Query!
Timepoint [80]
0
0
1 year
Query!
Secondary outcome [81]
0
0
Number of Participants With All Coronary Revascularization
Query!
Assessment method [81]
0
0
Revascularization includes TLR, TVR excluding TLR, and non TVR.
Query!
Timepoint [81]
0
0
2 years
Query!
Secondary outcome [82]
0
0
Number of Participants With All Coronary Revascularization
Query!
Assessment method [82]
0
0
Revascularization includes TLR, TVR excluding TLR, and non TVR.
Query!
Timepoint [82]
0
0
3 years
Query!
Secondary outcome [83]
0
0
Number of Participants With All Coronary Revascularization
Query!
Assessment method [83]
0
0
Revascularization includes TLR, TVR excluding TLR, and non TVR.
Query!
Timepoint [83]
0
0
4 years
Query!
Secondary outcome [84]
0
0
Number of Participants With All Coronary Revascularization
Query!
Assessment method [84]
0
0
Revascularization includes TLR, TVR excluding TLR, and non TVR.
Query!
Timepoint [84]
0
0
5 years
Query!
Secondary outcome [85]
0
0
Number of Participants Experienced All Death/All MI
Query!
Assessment method [85]
0
0
All deaths includes
Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Those MIs which are not Q-wave MI
Query!
Timepoint [85]
0
0
In-hospital (= 7 days post index procedure)
Query!
Secondary outcome [86]
0
0
Number of Participants Experienced All Death/All MI
Query!
Assessment method [86]
0
0
All deaths includes
Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Those MIs which are not Q-wave MI
Query!
Timepoint [86]
0
0
30 days
Query!
Secondary outcome [87]
0
0
Number of Participants Experienced All Death/All MI
Query!
Assessment method [87]
0
0
All deaths includes
Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Those MIs which are not Q-wave MI
Query!
Timepoint [87]
0
0
90 days
Query!
Secondary outcome [88]
0
0
Number of Participants Experienced All Death/All MI
Query!
Assessment method [88]
0
0
All deaths includes
Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Those MIs which are not Q-wave MI
Query!
Timepoint [88]
0
0
180 days
Query!
Secondary outcome [89]
0
0
Number of Participants Experienced All Death/All MI
Query!
Assessment method [89]
0
0
All deaths includes
Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Those MIs which are not Q-wave MI
Query!
Timepoint [89]
0
0
270 days
Query!
Secondary outcome [90]
0
0
Number of Participants Experienced All Death/All MI
Query!
Assessment method [90]
0
0
All deaths includes
Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Those MIs which are not Q-wave MI
Query!
Timepoint [90]
0
0
1 year
Query!
Secondary outcome [91]
0
0
Number of Participants Experienced All Death/All MI
Query!
Assessment method [91]
0
0
All deaths includes
Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Those MIs which are not Q-wave MI
Query!
Timepoint [91]
0
0
2 years
Query!
Secondary outcome [92]
0
0
Number of Participants Experienced All Death/All MI
Query!
Assessment method [92]
0
0
All deaths includes
Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Those MIs which are not Q-wave MI
Query!
Timepoint [92]
0
0
3 years
Query!
Secondary outcome [93]
0
0
Number of Participants Experienced All Death/All MI
Query!
Assessment method [93]
0
0
All deaths includes
Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Those MIs which are not Q-wave MI
Query!
Timepoint [93]
0
0
4 years
Query!
Secondary outcome [94]
0
0
Number of Participants Experienced All Death/All MI
Query!
Assessment method [94]
0
0
All deaths includes
Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Those MIs which are not Q-wave MI
Query!
Timepoint [94]
0
0
5 years
Query!
Secondary outcome [95]
0
0
Number of Participants Experienced Cardiac Death/All MI
Query!
Assessment method [95]
0
0
Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Query!
Timepoint [95]
0
0
In-hospital (= 7 days post index procedure)
Query!
Secondary outcome [96]
0
0
Number of Participants Experienced Cardiac Death/All MI
Query!
Assessment method [96]
0
0
Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Query!
Timepoint [96]
0
0
30 days
Query!
Secondary outcome [97]
0
0
Number of Participants Experienced Cardiac Death/All MI
Query!
Assessment method [97]
0
0
Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Query!
Timepoint [97]
0
0
90 days
Query!
Secondary outcome [98]
0
0
Number of Participants Experienced Cardiac Death/All MI
Query!
Assessment method [98]
0
0
Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Query!
Timepoint [98]
0
0
180 days
Query!
Secondary outcome [99]
0
0
Number of Participants Experienced Cardiac Death/All MI
Query!
Assessment method [99]
0
0
Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Query!
Timepoint [99]
0
0
270 days
Query!
Secondary outcome [100]
0
0
Number of Participants Experienced Cardiac Death/All MI
Query!
Assessment method [100]
0
0
Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Query!
Timepoint [100]
0
0
1 year
Query!
Secondary outcome [101]
0
0
Number of Participants Experienced Cardiac Death/All MI
Query!
Assessment method [101]
0
0
Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Query!
Timepoint [101]
0
0
2 years
Query!
Secondary outcome [102]
0
0
Number of Participants Experienced Cardiac Death/All MI
Query!
Assessment method [102]
0
0
Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Query!
Timepoint [102]
0
0
3 years
Query!
Secondary outcome [103]
0
0
Number of Participants Experienced Cardiac Death/All MI
Query!
Assessment method [103]
0
0
Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Query!
Timepoint [103]
0
0
4 years
Query!
Secondary outcome [104]
0
0
Number of Participants Experienced Cardiac Death/All MI
Query!
Assessment method [104]
0
0
Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Query!
Timepoint [104]
0
0
5 years
Query!
Secondary outcome [105]
0
0
Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)
Query!
Assessment method [105]
0
0
Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).
Query!
Timepoint [105]
0
0
In-hospital (= 7 days post index procedure)
Query!
Secondary outcome [106]
0
0
Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)
Query!
Assessment method [106]
0
0
Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).
Query!
Timepoint [106]
0
0
30 days
Query!
Secondary outcome [107]
0
0
Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)
Query!
Assessment method [107]
0
0
Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).
Query!
Timepoint [107]
0
0
90 days
Query!
Secondary outcome [108]
0
0
Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)
Query!
Assessment method [108]
0
0
Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).
Query!
Timepoint [108]
0
0
180 days
Query!
Secondary outcome [109]
0
0
Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)
Query!
Assessment method [109]
0
0
Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).
Query!
Timepoint [109]
0
0
270 days
Query!
Secondary outcome [110]
0
0
Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)
Query!
Assessment method [110]
0
0
Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).
Query!
Timepoint [110]
0
0
1 year
Query!
Secondary outcome [111]
0
0
Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)
Query!
Assessment method [111]
0
0
Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).
Query!
Timepoint [111]
0
0
2 years
Query!
Secondary outcome [112]
0
0
Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)
Query!
Assessment method [112]
0
0
Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).
Query!
Timepoint [112]
0
0
3 years
Query!
Secondary outcome [113]
0
0
Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)
Query!
Assessment method [113]
0
0
Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).
Query!
Timepoint [113]
0
0
4 years
Query!
Secondary outcome [114]
0
0
Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)
Query!
Assessment method [114]
0
0
Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).
Query!
Timepoint [114]
0
0
5 years
Query!
Secondary outcome [115]
0
0
Number of Participants Experienced Cardiac Death/All MI/ID-TLR (Major Adverse Cardiac Events-MACE)
Query!
Assessment method [115]
0
0
Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).
Query!
Timepoint [115]
0
0
In-hospital (= 7 days post index procedure)
Query!
Secondary outcome [116]
0
0
Number of Participants Experienced With Cardiac Death/All MI/ID-TLR (MACE)
Query!
Assessment method [116]
0
0
Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).
Query!
Timepoint [116]
0
0
30 days
Query!
Secondary outcome [117]
0
0
Number of Participants Experienced Cardiac Death/All MI/ID-TLR (MACE)
Query!
Assessment method [117]
0
0
Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).
Query!
Timepoint [117]
0
0
90 days
Query!
Secondary outcome [118]
0
0
Number of Participants Experienced Cardiac Death/All MI/ID-TLR (MACE)
Query!
Assessment method [118]
0
0
Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).
Query!
Timepoint [118]
0
0
180 days
Query!
Secondary outcome [119]
0
0
Number of Participants Experienced Cardiac Death/All MI/ID-TLR (MACE)
Query!
Assessment method [119]
0
0
Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).
Query!
Timepoint [119]
0
0
270 days
Query!
Secondary outcome [120]
0
0
Number of Participants Experienced Cardiac Death/All MI/ID-TLR (MACE)
Query!
Assessment method [120]
0
0
Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).
Query!
Timepoint [120]
0
0
1 year
Query!
Secondary outcome [121]
0
0
Number of Participants Experienced Cardiac Death/All MI/ID-TLR (MACE)
Query!
Assessment method [121]
0
0
Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).
Query!
Timepoint [121]
0
0
2 years
Query!
Secondary outcome [122]
0
0
Number of Participants Experienced Cardiac Death/All MI/ID-TLR (MACE)
Query!
Assessment method [122]
0
0
Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).
Query!
Timepoint [122]
0
0
3 years
Query!
Secondary outcome [123]
0
0
Number of Participants Experienced Cardiac Death/All MI/ID-TLR (MACE)
Query!
Assessment method [123]
0
0
Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).
Query!
Timepoint [123]
0
0
4 years
Query!
Secondary outcome [124]
0
0
Number of Participants Experienced Cardiac Death/All MI/ID-TLR (MACE)
Query!
Assessment method [124]
0
0
Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).
Query!
Timepoint [124]
0
0
5 years
Query!
Secondary outcome [125]
0
0
Number of Participants Experienced Cardiac Death/All MI/ID-TLR/ID-TVR, Non TL (Target Vessel Failure, TVF)
Query!
Assessment method [125]
0
0
Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).
Query!
Timepoint [125]
0
0
In-hospital (= 7 days post index procedure)
Query!
Secondary outcome [126]
0
0
Number of Participants Experienced Cardiac Death/All MI/ID-TLR/ID-TVR, Non TL (TVF)
Query!
Assessment method [126]
0
0
Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).
Query!
Timepoint [126]
0
0
30 days
Query!
Secondary outcome [127]
0
0
Number of Participants Experienced Cardiac Death/All MI/ID-TLR/ID-TVR, Non TL (TVF)
Query!
Assessment method [127]
0
0
Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).
Query!
Timepoint [127]
0
0
90 days
Query!
Secondary outcome [128]
0
0
Number of Participants Experienced Cardiac Death/All MI/ID-TLR/ID-TVR, Non TL (TVF)
Query!
Assessment method [128]
0
0
Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).
Query!
Timepoint [128]
0
0
180 days
Query!
Secondary outcome [129]
0
0
Number of Participants Experienced Cardiac Death/All MI/ID-TLR/ID-TVR, Non TL (TVF)
Query!
Assessment method [129]
0
0
Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).
Query!
Timepoint [129]
0
0
270 days
Query!
Secondary outcome [130]
0
0
Number of Participants Experienced Cardiac Death/All MI/ID-TLR/ID-TVR, Non TL (TVF)
Query!
Assessment method [130]
0
0
Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).
Query!
Timepoint [130]
0
0
1 year
Query!
Secondary outcome [131]
0
0
Number of Participants Experienced Cardiac Death/All MI/ID-TLR/ID-TVR, Non TL (TVF)
Query!
Assessment method [131]
0
0
Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).
Query!
Timepoint [131]
0
0
2 years
Query!
Secondary outcome [132]
0
0
Number of Participants Experienced Cardiac Death/All MI/ID-TLR/ID-TVR, Non TL (TVF)
Query!
Assessment method [132]
0
0
Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).
Query!
Timepoint [132]
0
0
3 years
Query!
Secondary outcome [133]
0
0
Number of Participants Experienced Cardiac Death/All MI/ID-TLR/ID-TVR, Non TL (TVF)
Query!
Assessment method [133]
0
0
Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).
Query!
Timepoint [133]
0
0
4 years
Query!
Secondary outcome [134]
0
0
Number of Participants Experienced Cardiac Death/All MI/ID-TLR/ID-TVR, Non TL (TVF)
Query!
Assessment method [134]
0
0
Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).
Query!
Timepoint [134]
0
0
5 years
Query!
Secondary outcome [135]
0
0
Number of Participants Experienced Death/All MI/All Revascularization (DMR)
Query!
Assessment method [135]
0
0
DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.
Query!
Timepoint [135]
0
0
In-hospital (= 7 days post index procedure)
Query!
Secondary outcome [136]
0
0
Number of Participants Experienced Death/All MI/All Revascularization (DMR)
Query!
Assessment method [136]
0
0
DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.
Query!
Timepoint [136]
0
0
30 days
Query!
Secondary outcome [137]
0
0
Number of Participants Experienced Death/All MI/All Revascularization (DMR)
Query!
Assessment method [137]
0
0
DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.
Query!
Timepoint [137]
0
0
90 days
Query!
Secondary outcome [138]
0
0
Number of Participants Experienced Death/All MI/All Revascularization (DMR)
Query!
Assessment method [138]
0
0
DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.
Query!
Timepoint [138]
0
0
180 days
Query!
Secondary outcome [139]
0
0
Number of Participants Experienced Death/All MI/All Revascularization (DMR)
Query!
Assessment method [139]
0
0
DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.
Query!
Timepoint [139]
0
0
270 days
Query!
Secondary outcome [140]
0
0
Number of Participants Experienced Death/All MI/All Revascularization (DMR)
Query!
Assessment method [140]
0
0
DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.
Query!
Timepoint [140]
0
0
1 year
Query!
Secondary outcome [141]
0
0
Number of Participants Experienced Death/All MI/All Revascularization (DMR)
Query!
Assessment method [141]
0
0
DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.
Query!
Timepoint [141]
0
0
2 years
Query!
Secondary outcome [142]
0
0
Number of Participants Experienced Death/All MI/All Revascularization (DMR)
Query!
Assessment method [142]
0
0
DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.
Query!
Timepoint [142]
0
0
3 years
Query!
Secondary outcome [143]
0
0
Number of Participants Experienced Death/All MI/All Revascularization (DMR)
Query!
Assessment method [143]
0
0
DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.
Query!
Timepoint [143]
0
0
4 years
Query!
Secondary outcome [144]
0
0
Number of Participants Experienced Death/All MI/All Revascularization (DMR)
Query!
Assessment method [144]
0
0
DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.
Query!
Timepoint [144]
0
0
5 years
Query!
Secondary outcome [145]
0
0
Number of Participants With Acute Scaffold/Stent Thrombosis (Per Academic Research Consortium (ARC) Definition)
Query!
Assessment method [145]
0
0
Stent thrombosis was defined by Academic Research Consortium (ARC) criteria as definite (angiographic confirmation with at least one of the following: acute onset of ischemic symptoms at rest, new ischemic ECG changes that suggest acute ischemia or typical rise and fall of cardiac biomarkers OR pathological confirmation at autopsy or via examination of tissue retrieved following thrombectomy), probable (any unexplained death within the first 30 days or, regardless of the time after the index procedure, any Myocardial infarction (MI) related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation and in the absence of any other obvious cause), and possible (any unexplained death from 30 days after intracoronary stenting until end of trial follow-up). Stent thrombosis was categorized as acute (0-24 hours post stent implantation), Subacute (>24 hours to 30 days post stent implantation), late (>30 days to 1 year post stent implantation).
Query!
Timepoint [145]
0
0
0 - 24 hours post stent implantation
Query!
Secondary outcome [146]
0
0
Number of Participants With Subacute Scaffold/Stent Thrombosis (Per ARC Definition)
Query!
Assessment method [146]
0
0
Stent thrombosis was defined by Academic Research Consortium (ARC) criteria as definite (angiographic confirmation with at least one of the following: acute onset of ischemic symptoms at rest, new ischemic ECG changes that suggest acute ischemia or typical rise and fall of cardiac biomarkers OR pathological confirmation at autopsy or via examination of tissue retrieved following thrombectomy), probable (any unexplained death within the first 30 days or, regardless of the time after the index procedure, any Myocardial infarction (MI) related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation and in the absence of any other obvious cause), and possible (any unexplained death from 30 days after intracoronary stenting until end of trial follow-up). Stent thrombosis was categorized as acute (0-24 hours post stent implantation), Subacute (>24 hours to 30 days post stent implantation), late (>30 days to 1 year post stent implantation).
Query!
Timepoint [146]
0
0
>24 hours - 30 days post stent implantation
Query!
Secondary outcome [147]
0
0
Number of Participants With Late Scaffold/Stent Thrombosis (Per ARC Definition)
Query!
Assessment method [147]
0
0
Stent thrombosis was defined by Academic Research Consortium (ARC) criteria as definite (angiographic confirmation with at least one of the following: acute onset of ischemic symptoms at rest, new ischemic ECG changes that suggest acute ischemia or typical rise and fall of cardiac biomarkers OR pathological confirmation at autopsy or via examination of tissue retrieved following thrombectomy), probable (any unexplained death within the first 30 days or, regardless of the time after the index procedure, any Myocardial infarction (MI) related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation and in the absence of any other obvious cause), and possible (any unexplained death from 30 days after intracoronary stenting until end of trial follow-up). Stent thrombosis was categorized as acute (0-24 hours post stent implantation), Subacute (>24 hours to 30 days post stent implantation), late (>30 days to 1 year post stent implantation).
Query!
Timepoint [147]
0
0
30 days - 1 year post stent implantation
Query!
Secondary outcome [148]
0
0
Number of Participants With Cumulative Scaffold/Stent Thrombosis (Per ARC Definition)
Query!
Assessment method [148]
0
0
Stent thrombosis was defined by Academic Research Consortium (ARC) criteria as definite (angiographic confirmation with at least one of the following: acute onset of ischemic symptoms at rest, new ischemic ECG changes that suggest acute ischemia or typical rise and fall of cardiac biomarkers OR pathological confirmation at autopsy or via examination of tissue retrieved following thrombectomy), probable (any unexplained death within the first 30 days or, regardless of the time after the index procedure, any Myocardial infarction (MI) related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation and in the absence of any other obvious cause), and possible (any unexplained
Query!
Timepoint [148]
0
0
0 to 730 Days
Query!
Secondary outcome [149]
0
0
Number of Participants With Rehospitalization
Query!
Assessment method [149]
0
0
Coronary artery disease (CAD) related
Cardiovascular, non-CAD related
Non-cardiovascular related
Query!
Timepoint [149]
0
0
30 days
Query!
Secondary outcome [150]
0
0
Number of Participants With Rehospitalization
Query!
Assessment method [150]
0
0
CAD related
Cardiovascular, non-CAD related
Non-cardiovascular related
Query!
Timepoint [150]
0
0
90 days
Query!
Secondary outcome [151]
0
0
Number of Participants With Rehospitalization
Query!
Assessment method [151]
0
0
CAD related
Cardiovascular, non-CAD related
Non-cardiovascular related
Query!
Timepoint [151]
0
0
180 days
Query!
Secondary outcome [152]
0
0
Number of Participants With Rehospitalization
Query!
Assessment method [152]
0
0
CAD related
Cardiovascular, non-CAD related
Non-cardiovascular related
Query!
Timepoint [152]
0
0
270 days
Query!
Secondary outcome [153]
0
0
Number of Participants With Rehospitalization
Query!
Assessment method [153]
0
0
CAD related
Cardiovascular, non-CAD related
Non-cardiovascular related
Query!
Timepoint [153]
0
0
1 year
Query!
Secondary outcome [154]
0
0
Number of Participants With Rehospitalization
Query!
Assessment method [154]
0
0
CAD related
Cardiovascular, non-CAD related
Non-cardiovascular related
Query!
Timepoint [154]
0
0
2 years
Query!
Secondary outcome [155]
0
0
Number of Participants With Rehospitalization
Query!
Assessment method [155]
0
0
CAD related
Cardiovascular, non-CAD related
Non-cardiovascular related
Query!
Timepoint [155]
0
0
3 years
Query!
Secondary outcome [156]
0
0
Number of Participants With Rehospitalization
Query!
Assessment method [156]
0
0
CAD related
Cardiovascular, non-CAD related
Non-cardiovascular related
Query!
Timepoint [156]
0
0
4 years
Query!
Secondary outcome [157]
0
0
Number of Participants With Rehospitalization
Query!
Assessment method [157]
0
0
CAD related
Cardiovascular, non-CAD related
Non-cardiovascular related
Query!
Timepoint [157]
0
0
5 years
Query!
Secondary outcome [158]
0
0
Number of Participants With Repeat Coronary Arteriography
Query!
Assessment method [158]
0
0
Query!
Timepoint [158]
0
0
In-hospital (= 7 days post index procedure)
Query!
Secondary outcome [159]
0
0
Number of Participants With Repeat Coronary Arteriography
Query!
Assessment method [159]
0
0
Query!
Timepoint [159]
0
0
30 days
Query!
Secondary outcome [160]
0
0
Number of Participants With Repeat Coronary Arteriography
Query!
Assessment method [160]
0
0
Query!
Timepoint [160]
0
0
90 days
Query!
Secondary outcome [161]
0
0
Number of Participants With Repeat Coronary Arteriography
Query!
Assessment method [161]
0
0
Query!
Timepoint [161]
0
0
180 days
Query!
Secondary outcome [162]
0
0
Number of Participants With Repeat Coronary Arteriography
Query!
Assessment method [162]
0
0
Query!
Timepoint [162]
0
0
270 days
Query!
Secondary outcome [163]
0
0
Number of Participants With Repeat Coronary Arteriography
Query!
Assessment method [163]
0
0
Query!
Timepoint [163]
0
0
1 year
Query!
Secondary outcome [164]
0
0
Number of Participants With Repeat Coronary Arteriography
Query!
Assessment method [164]
0
0
Query!
Timepoint [164]
0
0
2 years
Query!
Secondary outcome [165]
0
0
Number of Participants With Repeat Coronary Arteriography
Query!
Assessment method [165]
0
0
Query!
Timepoint [165]
0
0
3 years
Query!
Secondary outcome [166]
0
0
Number of Participants With Repeat Coronary Arteriography
Query!
Assessment method [166]
0
0
Query!
Timepoint [166]
0
0
4 years
Query!
Secondary outcome [167]
0
0
Number of Participants With Repeat Coronary Arteriography
Query!
Assessment method [167]
0
0
Query!
Timepoint [167]
0
0
5 years
Query!
Secondary outcome [168]
0
0
Number of Participants With Target Lesion Failure (TLF)
Query!
Assessment method [168]
0
0
The analysis will be based on 4610 subjects (2000 primary analysis subjects of ABSORB III and 2610 subjects of ABSORB IV)
Query!
Timepoint [168]
0
0
1 year
Query!
Eligibility
Key inclusion criteria
General
1. Subject must be at least 18 years of age.
2. Subject or a legally authorized representative must provide written Informed Consent
prior to any study related procedure, per site requirements.
3. Subject must have evidence of myocardial ischemia (e.g., silent ischemia, stable or
unstable angina, non-ST-segment elevation MI (NSTEMI), OR recent ST-segment elevation
MI (STEMI). Patients with stable coronary syndromes can be enrolled any time after
symptom onset if eligibility criteria are otherwise met. Patients with acute coronary
syndrome can be enrolled under the following conditions:
1. Unstable angina or NSTEMI within 2 weeks of the index procedure.
2. STEMI > 72 hours = 2 weeks prior to the index procedure.
Note: Subjects with Unstable angina (UA) or NSTEMI or STEMI occurring > 2 weeks of the
index procedure can be included in the trial but should be categorized based on their
current angina class.
4. Subjects must be suitable for PCI. Subjects with stable angina or silent ischemia and
< 70% diameter stenosis must have objective signs of ischemia as determined by one of
the following: abnormal stress echocardiogram, nuclear scan, electrocardiogram (ECG),
positron emission tomography (PET), magnetic resonance imaging (MRI), and/or
fractional flow reserve (FFR).
(Note: subject with silent ischemia must have a prior history of typical angina,
angina-equivalent symptoms, or atypical angina within the past year to be included in
the trial.)
5. Subject must be an acceptable candidate for coronary artery bypass graft (CABG)
surgery.
6. Female subject of childbearing potential who does not plan pregnancy for up to 1 year
following the index procedure. For a female subject of childbearing potential a
pregnancy test must be performed with negative results known within 7 days prior to
the index procedure per site standard.
7. Female subject is not breast-feeding at the time of the screening visit and will not
be breast-feeding for at least 1 year following the index procedure.
8. Subject agrees to not participate in any other investigational or invasive clinical
study for a period of 5 years following the index procedure.
Angiographic
Treatment of up to three de novo lesions in a maximum of two epicardial vessels, with a
maximum of two lesions per epicardial vessel. If only a single lesion is to be treated, it
must be a target lesion. Up to one non-target lesion can be treated. Non-target lesion
treatment can occur only in a non-target vessel.
If there are two target lesions within the same epicardial vessel, the two target lesions
must be at least 15 mm apart per visual estimation; otherwise this is considered as a
single target lesion for lesion (and stent) length determination and must be treated with a
single study device.
1. Target lesion(s) must be located in a native coronary artery with a visually estimated
or quantitatively assessed %DS of =50% and < 100%, with a thrombolysis in myocardial
infarction (TIMI) flow of = 1, and one of the following: stenosis = 70%, an abnormal
functional test (e.g., fractional flow reserve =0.80 AND/OR a positive stress test), or
presentation with an acute coronary syndrome (unstable angina or NSTEMI within 2 weeks of
index procedure, or STEMI >72 hours but = 2 weeks prior to the index procedure).
1. Target lesion(s) must be located in a native coronary artery with reference vessel
diameter (RVD) by visual estimation of = 2.50 mm and = 3.75 mm.
2. Target lesion(s) must be located in a native coronary artery with length by visual
estimation of = 24 mm.
Note: Subjects with Unstable angina (UA) or NSTEMI or STEMI occurring > 2 weeks of the
index procedure can be included in the trial but should be categorized based on their
current angina class.
Note: To exclude enrollment of excessively small vessels, if the operator believes that
based on visual angiographic assessments, the distal reference vessel diameter is = 2.75 mm
such that the plan is to implant a 2.5 mm device (stent or scaffold) in a target lesion, it
is strongly recommended that either on-line QCA or intravascular imaging (ultrasound or
optical coherence tomography) is used and demonstrates that the measured distal RVD for
this target lesion is = 2.50 mm (by at least one of these imaging modalities). This
measurement may be performed before or after pre-dilatation, but before randomization. If
the distal RVD measures <2.5 mm, that lesion IS NOT ELIGIBLE for randomization. Such a
lesion may be treated as a non-target lesion.
General
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. Any surgery requiring general anesthesia or discontinuation of aspirin and/or a P2Y12
receptor inhibitor is planned within 12 months after the procedure.
2. Subject has known hypersensitivity or contraindication to device material and its
degradants (everolimus, poly (L-lactide), poly (DL-lactide), lactide, lactic acid) and
cobalt, chromium, nickel, platinum, tungsten, acrylic and fluoro polymers that cannot
be adequately pre-medicated. Subject has a known contrast sensitivity that cannot be
adequately pre-medicated.
3. Subject has known allergic reaction, hypersensitivity or contraindication to any of
the following: aspirin; or clopidogrel and prasugrel and ticagrelor; or heparin and
bivalirudin, and therefore cannot be adequately treated with study medications.
4. Subject had an acute STEMI (appropriate clinical syndrome with =1 mm of ST-segment
elevation in =2 contiguous leads) within 72 hours of the index procedure.
5. Subject has a cardiac arrhythmia identified at the time of screening for which at
least one of the following criteria is met:
1. Subject requires coumadin or any other agent for chronic oral anticoagulation.
2. Subject is likely to become hemodynamically unstable due to their arrhythmia.
3. Subject has poor survival prognosis due to their arrhythmia.
6. Subject has a left ventricular ejection fraction (LVEF) < 30% assessed by any
quantitative method, including but not limited to echocardiography, MRI,
multiple-gated acquisition (MUGA) scan, contrast left ventriculography, PET scan, etc.
LVEF may be obtained within 6 months prior to the procedure for subjects with stable
CAD. For subjects presenting with acute coronary syndrome (ACS), LVEF must be assessed
within 1 week of the index procedure and after ACS presentation, which may include
contrast left ventriculography during the index procedure but prior to randomization
in order to confirm the subject's eligibility.
7. Subject has undergone prior PCI within the target vessel during the last 12 months.
Prior PCI within the non-target vessel or any peripheral intervention is acceptable if
performed anytime >30 days before the index procedure, or between a minimum of 24
hours and 30 days before the index procedure if successful and uncomplicated.
8. Subject requires future staged PCI of any lesion other than a target lesion identified
at the time of index procedure; or subject requires future peripheral vascular
interventions < 30 days after the index procedure.
9. Subject has received any solid organ transplants or is on a waiting list for any solid
organ transplants.
10. At the time of screening, the subject has a malignancy that is not in remission.
11. Subject is receiving immunosuppressant therapy or has known immunosuppressive or
severe autoimmune disease that requires chronic immunosuppressive therapy (e.g., human
immunodeficiency virus, systemic lupus erythematosus, etc.). Note: corticosteroids are
not included as immunosuppressant therapy.
12. Subject has previously received or is scheduled to receive radiotherapy to a coronary
artery (vascular brachytherapy), or the chest/mediastinum.
13. Subject is receiving or will require chronic anticoagulation therapy (e.g., coumadin,
dabigatran, apixaban, rivaroxaban, edoxaban or any other related agent for any
reason).
14. Subject has a platelet count < 100,000 cells/mm3 or > 700,000 cells/mm3.
15. Subject has a documented or suspected hepatic disorder as defined as cirrhosis or
Child-Pugh = Class B.
16. Subject has renal insufficiency as defined as an estimated glomerular filtration rate
(GFR) < 30 ml/min/1.73m2 or dialysis at the time of screening.
17. Subject is high risk of bleeding for any reason; has a history of bleeding diathesis
or coagulopathy; has had a significant gastrointestinal or significant urinary bleed
within the past six months.
18. Subject has had a cerebrovascular accident or transient ischemic neurological attack
(TIA) within the past six months, or any prior intracranial bleed, or any permanent
neurologic defect, or any known intracranial pathology (e.g. aneurysm, arteriovenous
malformation, etc.).
19. Subject has extensive peripheral vascular disease that precludes safe 6 French sheath
insertion. Note: femoral arterial disease does not exclude the patient if radial
access may be used.
20. Subject has a life expectancy <5 years for any non-cardiac or cardiac cause.
21. Subject is in the opinion of the Investigator or designee, unable to comply with the
requirements of the study protocol or is unsuitable for the study for any reason. This
includes completion of Patient Reported Outcome instruments.
22. Subject is currently participating in another clinical trial that has not yet
completed its primary endpoint.
23. Subject is part of a vulnerable population who, in the judgment of the investigator,
is unable to give Informed Consent for reasons of incapacity, immaturity, adverse
personal circumstances or lack of autonomy. This may include: Individuals with a
mental disability, persons in nursing homes, children, impoverished persons, persons
in emergency situations, homeless persons, nomads, refugees, and those incapable of
giving informed consent. Vulnerable populations also may include members of a group
with a hierarchical structure such as university students, subordinate hospital and
laboratory personnel, employees of the Sponsor, members of the armed forces, and
persons kept in detention.
Angiographic
All exclusion criteria apply to the target lesion(s) or target vessel(s).
1. Unsuccessful pre-dilatation, defined as the presence of one or more of the following
(note: successful pre-dilatation of at least one target lesion is required prior to
randomization):
1. Residual %diameter stenosis (DS) after pre-dilatation is = 40% (per visual
estimation). Note: achieving a %DS = 20% prior to randomization is strongly
recommended.
2. TIMI flow grade <3 (per visual estimation).
3. Any angiographic complication (e.g. distal embolization, side branch closure).
4. Any dissection NHLBI grade D-F.
5. Any chest pain lasting > 5 minutes.
6. Any ST-segment depression or elevation lasting > 5 minutes.
2. Lesion is located in left main or there is a =30% diameter stenosis in the left main
(unless the left main lesion is a protected left main (i.e. a patent bypass graft to
the LAD and/or LCX arteries is present), and there is no intention to treat the
protected left main lesion).
3. Aorto-ostial right coronary artery (RCA) lesion (within 3 mm of the ostium).
4. Lesion located within 3 mm of the origin of the left anterior descending artery (LAD)
or left circumflex artery (LCX).
5. Lesion involving a bifurcation with a:
1. side branch = 2 mm in diameter, or
2. side branch with either an ostial or non-ostial lesion with diameter stenosis
>50%, or
3. side branch requiring dilatation
6. Anatomy proximal to or within the lesion that may impair delivery of the Absorb BVS or
XIENCE stent:
1. Extreme angulation (= 90°) proximal to or within the target lesion.
2. Excessive tortuosity (= two 45° angles) proximal to or within the target lesion.
3. Moderate or heavy calcification proximal to or within the target lesion. If
intravascular ultrasound (IVUS) used, subject must be excluded if calcium arc in
the vessel prior to the lesion or within the lesion is = 180°.
7. Lesion or vessel involves a myocardial bridge.
8. Vessel has been previously treated with a stent and the target lesion is within 5 mm
proximal or distal to a previously stented lesion.
9. Target lesion located within an arterial or saphenous vein graft or distal to any
arterial or saphenous vein graft.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Not Applicable
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/07/2014
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
6/04/2022
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
2604
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC,WA
Query!
Recruitment hospital [1]
0
0
Liverpool Hospital - Liverpool
Query!
Recruitment hospital [2]
0
0
The Prince Charles Hospital - Brisbane
Query!
Recruitment hospital [3]
0
0
Royal Brisbane and Women's Hospital - Herston
Query!
Recruitment hospital [4]
0
0
St Vincent's Hospital Melbourne - Fitzroy
Query!
Recruitment hospital [5]
0
0
Fiona Stanley Hospital - Murdoch
Query!
Recruitment hospital [6]
0
0
Royal Perth Hospital - Perth
Query!
Recruitment postcode(s) [1]
0
0
2170 - Liverpool
Query!
Recruitment postcode(s) [2]
0
0
4032 - Brisbane
Query!
Recruitment postcode(s) [3]
0
0
4029 - Herston
Query!
Recruitment postcode(s) [4]
0
0
3065 - Fitzroy
Query!
Recruitment postcode(s) [5]
0
0
6150 - Murdoch
Query!
Recruitment postcode(s) [6]
0
0
6001 - Perth
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Arkansas
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
California
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Colorado
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Connecticut
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Florida
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Georgia
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Illinois
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Indiana
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Kentucky
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Louisiana
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Maine
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Maryland
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Massachusetts
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Michigan
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Mississippi
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Missouri
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Montana
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Nebraska
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
New Hampshire
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
New Jersey
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
New York
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
North Carolina
Query!
Country [25]
0
0
United States of America
Query!
State/province [25]
0
0
Ohio
Query!
Country [26]
0
0
United States of America
Query!
State/province [26]
0
0
Oklahoma
Query!
Country [27]
0
0
United States of America
Query!
State/province [27]
0
0
Oregon
Query!
Country [28]
0
0
United States of America
Query!
State/province [28]
0
0
Pennsylvania
Query!
Country [29]
0
0
United States of America
Query!
State/province [29]
0
0
Rhode Island
Query!
Country [30]
0
0
United States of America
Query!
State/province [30]
0
0
South Carolina
Query!
Country [31]
0
0
United States of America
Query!
State/province [31]
0
0
Tennessee
Query!
Country [32]
0
0
United States of America
Query!
State/province [32]
0
0
Texas
Query!
Country [33]
0
0
United States of America
Query!
State/province [33]
0
0
Virginia
Query!
Country [34]
0
0
United States of America
Query!
State/province [34]
0
0
Washington
Query!
Country [35]
0
0
Canada
Query!
State/province [35]
0
0
Ontario
Query!
Country [36]
0
0
Canada
Query!
State/province [36]
0
0
Quebec
Query!
Country [37]
0
0
Germany
Query!
State/province [37]
0
0
Baden-Württemberg
Query!
Country [38]
0
0
Germany
Query!
State/province [38]
0
0
Bavaria
Query!
Country [39]
0
0
Germany
Query!
State/province [39]
0
0
Berlin
Query!
Country [40]
0
0
Germany
Query!
State/province [40]
0
0
Hesse
Query!
Country [41]
0
0
Germany
Query!
State/province [41]
0
0
Lower Saxony
Query!
Country [42]
0
0
Germany
Query!
State/province [42]
0
0
North Rhine-Westphalia
Query!
Country [43]
0
0
Germany
Query!
State/province [43]
0
0
Rhineland-Palatinate
Query!
Country [44]
0
0
Germany
Query!
State/province [44]
0
0
Schleswig-Holstein
Query!
Country [45]
0
0
Singapore
Query!
State/province [45]
0
0
Singapore
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Abbott Medical Devices
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
ABSORB IV is a prospective, randomized (1:1, Absorb BVS to XIENCE), single-blind,
multi-center study, registering approximately 2610 subjects from approximately 140 sites in
the United States and outside the United States. ABSORB IV is a continuation of ABSORB III
(NCT01751906) trial which are maintained under one protocol because both trial designs are
related. The data from ABSORB III and ABSORB IV will be pooled to support the ABSORB IV
primary endpoint. Both the trials will evaluate the safety and effectiveness of Absorb BVS.
The ABSORB IV Randomized Controlled Trial (RCT) is designed to continue to evaluate the
safety and effectiveness as well as the potential short and long-term benefits of Abbott
Vascular Absorb™ Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
(once commercially available), as compared to the commercially approved, control stent
XIENCE.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT02173379
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Gregg W Stone, MD
Query!
Address
0
0
Columbia University Medical Center, New York, NY
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT02173379
Download to PDF